Logo image of CV

CAPSOVISION INC (CV) Stock Fundamental Analysis

NASDAQ:CV - US1409351079 - Common Stock

3.63 USD
+0.07 (+1.97%)
Last: 9/10/2025, 8:00:00 PM
3.63 USD
0 (0%)
After Hours: 9/10/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CV. CV was compared to 190 industry peers in the Health Care Equipment & Supplies industry. CV has a bad profitability rating. Also its financial health evaluation is rather negative. CV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CV has reported negative net income.
CV Yearly Net Income VS EBIT VS OCF VS FCFCV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of CV (-208.42%) is worse than 92.63% of its industry peers.
CV has a worse Return On Equity (-428.93%) than 83.68% of its industry peers.
Industry RankSector Rank
ROA -208.42%
ROE -428.93%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CV Yearly ROA, ROE, ROICCV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -50 -100

1.3 Margins

CV has a Gross Margin of 54.24%. This is comparable to the rest of the industry: CV outperforms 48.42% of its industry peers.
CV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CV Yearly Profit, Operating, Gross MarginsCV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

CV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CV remains at a similar level compared to 1 year ago.
CV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CV Yearly Shares OutstandingCV Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 10M 20M 30M 40M
CV Yearly Total Debt VS Total AssetsCV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 5M 10M 15M 20M

2.2 Solvency

CV has an Altman-Z score of -5.03. This is a bad value and indicates that CV is not financially healthy and even has some risk of bankruptcy.
CV's Altman-Z score of -5.03 is on the low side compared to the rest of the industry. CV is outperformed by 68.42% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that CV is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.22, CV is in line with its industry, outperforming 54.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z -5.03
ROIC/WACCN/A
WACC8.72%
CV Yearly LT Debt VS Equity VS FCFCV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 1.85 indicates that CV should not have too much problems paying its short term obligations.
The Current ratio of CV (1.85) is worse than 67.37% of its industry peers.
A Quick Ratio of 1.13 indicates that CV should not have too much problems paying its short term obligations.
CV has a Quick ratio of 1.13. This is in the lower half of the industry: CV underperforms 71.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.13
CV Yearly Current Assets VS Current LiabilitesCV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CV have decreased strongly by -76.06% in the last year.
CV shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.54%.
EPS 1Y (TTM)-76.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)20.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CV will show a very strong growth in Earnings Per Share. The EPS will grow by 25.49% on average per year.
The Revenue is expected to grow by 66.73% on average over the next years. This is a very strong growth
EPS Next Y-59.51%
EPS Next 2Y10.47%
EPS Next 3Y25.49%
EPS Next 5YN/A
Revenue Next Year23.4%
Revenue Next 2Y53.16%
Revenue Next 3Y66.73%
Revenue Next 5YN/A

3.3 Evolution

CV Yearly Revenue VS EstimatesCV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
CV Yearly EPS VS EstimatesCV Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CV Price Earnings VS Forward Price EarningsCV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CV Per share dataCV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as CV's earnings are expected to grow with 25.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.47%
EPS Next 3Y25.49%

More info and screens

0

5. Dividend

5.1 Amount

CV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAPSOVISION INC

NASDAQ:CV (9/10/2025, 8:00:00 PM)

After market: 3.63 0 (0%)

3.63

+0.07 (+1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners17.49%
Ins Owner Change40.4%
Market Cap169.78M
Analysts84
Price Target5.61 (54.55%)
Short Float %0.02%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-4.17%
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.44
P/FCF N/A
P/OCF N/A
P/B 36.6
P/tB 36.6
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.25
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -208.42%
ROE -428.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.24%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.13
Altman-Z -5.03
F-ScoreN/A
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-59.51%
EPS Next 2Y10.47%
EPS Next 3Y25.49%
EPS Next 5YN/A
Revenue 1Y (TTM)20.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year23.4%
Revenue Next 2Y53.16%
Revenue Next 3Y66.73%
Revenue Next 5YN/A
EBIT growth 1Y-75.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-75.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.99%
OCF growth 3YN/A
OCF growth 5YN/A